There have been significant developments in Tepezza hearing loss litigation over the past several months. As of January 2023 approximately 10 lawsuits have been filed nationwide. These case all contain allegations that Horizon Pharmaceuticals aggressively marketed Tepezza for thyroid eye disease without disclosing the risk of permanent hearing loss or tinnitus.
Despite mounting evidence and multiple updated studies from the Endocrine Society, Horizon has neither recalled Tepezza or changed the warning label.
The size of the Tepezza litigation is anticipated to grow significantly throughout 2023 as more individuals learn of the damaged associated from permanent hearing loss and/or tinnitus after Tepezza infusions.